At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 307 enrolled
Drug / intervention
pregabalin +2 moredrug
Likely dose
pregabalin 150 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind Randomized, Placebo-Controlled Study Of The Efficacy And Safety Of Pregabalin In The Treatment Of Subjects With Post-Operative Pain Following Total Knee Arthroplasty (TKA)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Mar 2, 2007·Updated Jan 22, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin and Placebo for Osteoarthritis and Postoperative Pain. Completed, enrolled 307 participants across 27 sites.
Detailed Summary
Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Postoperative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionDec 2008
TodayJul 2026
First PostedMar 2, 2007
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.3 years ago
Interventions
pregabalindrug
150 milligram (mg)/ day (double blind)
pregabalindrug
300 mg/day (double blind)
Placebodrug
Placebo